VA
Valiant Laboratories Ltd (VALIANTLAB)
₹94.91
Mkt cap
₹493 Cr
P/E ratio
30.40
P/B
1.55
Div yield
0.00%
ROE
−2.55%
ROCE
0.58%
EPS (TTM)
₹3.12
Book value
₹61
52W range
50–141
Sector
Healthcare
Price history
Previous close
Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals [1]
NSE VALIANTLABBSE 543998
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthModerate
TechnicalsNeutral
52-week range
−32.87% from high₹95
₹50+91.70% from low₹141
Current
₹94.91
Prev close
₹96.84
Day
−1.99%
Price performance
1D
−1.99%
1W
−9.58%
1M
−27.58%
3M
+3.55%
6M
+24.93%
1Y
+19.26%
YTD
+36.78%
Financials
Revenue, profit & margin
P/E ratio
30.4×
VALIANTLAB is 6% below the sector median of 32.5×
VALIANTLAB30.4×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 59.55 | 40.52 | 30.59 | 18.88 | 21.48 | 35.23 | 57.79 | 46.82 | 46.20 | 52.46 | 91.98 | 115.29 | 116.77 | |
| YoY Sales growth | -32.30% | -42.74% | -65.98% | -63.28% | -63.93% | -13.06% | +88.92% | +147.99% | +115.08% | +48.91% | +59.16% | +146.24% | +152.75% | |
| Expenses | 60.94 | 46.83 | 35.12 | 21.27 | 28.22 | 34.61 | 53.97 | 44.43 | 46.12 | 53.35 | 87.17 | 86.03 | 111.59 | |
| Operating Profit | -1.39 | -6.31 | -4.53 | -2.39 | -6.74 | 0.62 | 3.82 | 2.39 | 0.08 | -0.89 | 4.81 | 29.26 | 5.18 | |
| OPM % | -2.33% | -15.57% | -14.81% | -12.66% | -31.38% | 1.76% | 6.61% | 5.10% | 0.17% | -1.70% | 5.23% | 25.38% | 4.44% | |
| Other Income | 2.96 | 1.78 | 2.50 | 2.81 | 3.36 | 1.58 | -2.31 | 0.66 | 0.87 | 0.63 | 0.17 | 0.86 | 0.11 | |
| Interest | 0.02 | 0.02 | 0.02 | 0.05 | 0.01 | 0.06 | 0.05 | 0.07 | 0.14 | 0.68 | 1.01 | 1.07 | 0.96 | |
| Depreciation | 0.49 | 0.49 | 0.52 | 0.53 | 0.52 | 0.52 | 0.52 | 0.53 | 0.53 | 2.05 | 2.93 | 2.86 | 3.66 | |
| Profit before tax | 1.06 | -5.04 | -2.57 | -0.16 | -3.91 | 1.62 | 0.94 | 2.45 | 0.28 | -2.99 | 1.04 | 26.19 | 0.67 | |
| Tax % | 25.47% | -30.75% | -51.75% | 218.75% | 21.23% | -44.44% | 25.53% | 25.71% | 25.00% | 136.12% | -68.27% | 19.43% | 37.31% | |
| Net Profit | 0.79 | -3.50 | -1.24 | -0.51 | -4.74 | 2.35 | 0.70 | 1.82 | 0.20 | -7.06 | 1.76 | 21.10 | 0.41 | |
| EPS in Rs | 0.23 | -0.75 | -0.26 | -0.11 | -1.01 | 0.50 | 0.15 | 0.39 | 0.04 | -1.30 | 0.32 | 3.88 | 0.08 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202674.94%Promoter
Promoters74.94%
FIIs0.07%0.07
DIIs0.08%0.08
Public24.91%0.15
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Valiant Laborato | ₹94.91 | 30.43 | 493 | 0.00% | 0 | +105.00% | 117 | +152.75% | 0.58% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports3
Credit ratings6
Announcements5
Intimation Of Sad Demise Of The Member Of A Promoter Group Of The Company 15 Nov - Shri Chandrakant Vallabhaji Gogri of promoter group passed away on November 15, 2026.Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Nov - Copy of Newspaper Publication of Financial Results for quarter and half year ended September 30, 2026.Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026. 2 Nov - Board approved audited Q2/H1 FY27 standalone and consolidated results on Nov 2, 2026.Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter And Half Year Ended September 30, 2026. 2 Nov - Board approved audited standalone and consolidated results for quarter and half year ended September 30, 2026.Board Meeting Intimation for Financial Results For The Quarter And Half Year Ended September 30, 2026. 27 Oct - Board meeting on November 2, 2026 to approve Q2 and half-year FY2027 audited results.






